{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T09:12:25Z","timestamp":1780564345400,"version":"3.54.1"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"AstraZeneca Inc."}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1016\/j.ejca.2018.08.004","type":"journal-article","created":{"date-parts":[[2018,9,14]],"date-time":"2018-09-14T13:39:25Z","timestamp":1536932365000},"page":"127-136","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Fulvestrant plus goserelin versus anastrozole plus goserelin versus goserelin alone for hormone receptor-positive, HER2-negative tamoxifen-pretreated premenopausal women with recurrent or metastatic breast cancer (KCSG BR10-04): a multicentre, open-label, three-arm, randomised phase II trial (FLAG study)"],"prefix":"10.1016","volume":"103","author":[{"given":"Ji-Yeon","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seock-Ah","family":"Im","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyung Hae","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jungsil","family":"Ro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joohyuk","family":"Sohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jee Hyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeon Hee","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tae-Yong","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung-Bae","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keun Seok","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gun Min","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Se Hyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seonwoo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin Seok","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyung-Hun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Hee","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In Hae","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young-Hyuck","family":"Im","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.ejca.2018.08.004_bib1","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djv048","article-title":"Annual report to the Nation on the status of cancer, 1975-2011, featuring incidence of breast cancer subtypes by race\/ethnicity, poverty, and state","volume":"107","author":"Kohler","year":"2015","journal-title":"J Natl Cancer Inst"},{"issue":"6","key":"10.1016\/j.ejca.2018.08.004_bib2","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1586\/14737167.2014.949243","article-title":"The association of chemotherapy versus hormonal therapy and health outcomes among patients with hormone receptor-positive, HER2-negative metastatic breast cancer: experience from the patient perspective","volume":"14","author":"Gupta","year":"2014","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"3","key":"10.1016\/j.ejca.2018.08.004_bib3","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.breast.2012.03.003","article-title":"1st International consensus guidelines for advanced breast cancer (ABC 1)","volume":"21","author":"Cardoso","year":"2012","journal-title":"Breast"},{"issue":"25","key":"10.1016\/j.ejca.2018.08.004_bib4","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1200\/JCO.2016.67.1487","article-title":"Endocrine therapy for hormone receptor-positive metastatic breast cancer: American society of clinical oncology guideline","volume":"34","author":"Rugo","year":"2016","journal-title":"J Clin Oncol"},{"issue":"29","key":"10.1016\/j.ejca.2018.08.004_bib5","doi-asserted-by":"crossref","first-page":"3307","DOI":"10.1200\/JCO.2014.56.7479","article-title":"Chemotherapy and targeted therapy for women with human epidermal growth factor receptor 2-negative (or unknown) advanced breast cancer: American society of clinical oncology clinical practice guideline","volume":"32","author":"Partridge","year":"2014","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2018.08.004_bib6","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1093\/annonc\/mdw544","article-title":"ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 3)","volume":"28","author":"Cardoso","year":"2017","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2018.08.004_bib7","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1200\/JCO.1986.4.2.178","article-title":"Randomized trial of bilateral oophorectomy versus tamoxifen in premenopausal women with metastatic breast cancer","volume":"4","author":"Ingle","year":"1986","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2018.08.004_bib8","series-title":"All rights reserved. NCCN clinical practice guidelines in oncology (NCCN Guidelines\u00a9): breast cancer","author":"National Comprehensive Cancer Network I","year":"2017"},{"issue":"6","key":"10.1016\/j.ejca.2018.08.004_bib9","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.coph.2003.06.009","article-title":"Gonadotropin-releasing hormone antagonists","volume":"3","author":"Herbst","year":"2003","journal-title":"Curr Opin Pharmacol"},{"issue":"2","key":"10.1016\/j.ejca.2018.08.004_bib10","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1200\/JCO.2001.19.2.343","article-title":"Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials","volume":"19","author":"Klijn","year":"2001","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2018.08.004_bib11","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1093\/annonc\/mdw544","article-title":"ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 3)","volume":"28","author":"Cardoso","year":"2017","journal-title":"Ann Oncol"},{"issue":"22","key":"10.1016\/j.ejca.2018.08.004_bib12","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1200\/JCO.2000.18.22.3758","article-title":"Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex study group","volume":"18","author":"Nabholtz","year":"2000","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.ejca.2018.08.004_bib13","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s10549-007-9527-6","article-title":"Letrozole in advanced breast cancer: the PO25 trial","volume":"105","author":"Mouridsen","year":"2007","journal-title":"Breast Canc Res Treat"},{"issue":"30","key":"10.1016\/j.ejca.2018.08.004_bib14","doi-asserted-by":"crossref","first-page":"4883","DOI":"10.1200\/JCO.2007.14.4659","article-title":"Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European organisation for research and treatment of cancer breast cancer cooperative group","volume":"26","author":"Paridaens","year":"2008","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2018.08.004_bib15","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s10549-012-2192-4","article-title":"Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: follow-up analysis from the randomized 'FIRST' study","volume":"136","author":"Robertson","year":"2012","journal-title":"Breast Canc Res Treat"},{"issue":"10063","key":"10.1016\/j.ejca.2018.08.004_bib16","doi-asserted-by":"crossref","first-page":"2997","DOI":"10.1016\/S0140-6736(16)32389-3","article-title":"Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial","volume":"388","author":"Robertson","year":"2016","journal-title":"Lancet"},{"issue":"25","key":"10.1016\/j.ejca.2018.08.004_bib17","doi-asserted-by":"crossref","first-page":"3917","DOI":"10.1200\/JCO.2009.24.9565","article-title":"Phase II trial of anastrozole plus goserelin in the treatment of hormone receptor-positive, metastatic carcinoma of the breast in premenopausal women","volume":"28","author":"Carlson","year":"2010","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1016\/j.ejca.2018.08.004_bib18","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1016\/j.ejca.2012.03.002","article-title":"Ovarian function suppression and fulvestrant as endocrine therapy in premenopausal women with metastatic breast cancer","volume":"48","author":"Bartsch","year":"2012","journal-title":"Eur J Canc"},{"issue":"16","key":"10.1016\/j.ejca.2018.08.004_bib19","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1200\/JCO.2009.26.5884","article-title":"Phase II parallel group study showing comparable efficacy between premenopausal metastatic breast cancer patients treated with letrozole plus goserelin and postmenopausal patients treated with letrozole alone as first-line hormone therapy","volume":"28","author":"Park","year":"2010","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2018.08.004_bib20","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S1470-2045(15)00613-0","volume":"17","author":"Cristofanilli","year":"2016","journal-title":"Lancet Oncol"},{"issue":"27","key":"10.1016\/j.ejca.2018.08.004_bib21","doi-asserted-by":"crossref","first-page":"3308","DOI":"10.1200\/JCO.2015.65.8013","article-title":"Subtype-dependent relationship between young age at diagnosis and breast cancer survival","volume":"34","author":"Partridge","year":"2016","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2018.08.004_bib22","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1803164","article-title":"Tailoring adjuvant endocrine therapy for premenopausal breast cancer","volume":"379","author":"Francis","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2018.08.004_bib23","series-title":"False elevation of serum estradiol due to fulvestrant may lead to faulty therepeutic decisions: the need for meication lable warning","author":"Fattout LU","year":"2014"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095980491831116X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095980491831116X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:23:23Z","timestamp":1760732603000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S095980491831116X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":23,"alternative-id":["S095980491831116X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2018.08.004","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fulvestrant plus goserelin versus anastrozole plus goserelin versus goserelin alone for hormone receptor-positive, HER2-negative tamoxifen-pretreated premenopausal women with recurrent or metastatic breast cancer (KCSG BR10-04): a multicentre, open-label, three-arm, randomised phase II trial (FLAG study)","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2018.08.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}